Lincomycin Hydrochloride Injection Passes Generic Drug Consistency Evaluation
September 24, 2025
Source: drugdu
90
On September 23rd, Tianfang Pharmaceutical, a wholly-owned subsidiary of SINOPHARM, announced that it has received notification from the National Medical Products Administration (NMPA) that Lincomycin Hydrochloride Injection has passed the generic drug quality and efficacy consistency evaluation. This drug is primarily used to treat serious infections caused by susceptible strains of Streptococcus, Pneumococcus, and Staphylococcus. Passing the consistency evaluation will provide greater support in areas such as medical insurance payment and procurement by medical institutions, helping to enhance its market competitiveness. However, there is a risk that sales may not meet expectations due to policy and market factors.
https://finance.eastmoney.com/a/202509233521233113.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval December 12, 2025
- Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials December 12, 2025
- The ‘Sweetest’ HPV Vaccine Market is Gone | Haibin Interview December 12, 2025
- InnoCare Pharma announced that its first independently developed next-generation TRK inhibitor, zoletrazinib, has been approved for marketing in China December 12, 2025
- Is PD-1/VEGF dual antibody + ADC becoming the standard configuration? December 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
